FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
Results from the ILLUMINATE-A and ILLUMINATE-B studies demonstrate that Oxlumo addresses the underlying pathophysiology of PH1 in adults, children and infants, and we believe this newly approved medicine has the potential to change the course of this progressive disease,” said Akshay Vaishnaw, M.D., President of R&D at Alnylam.
52 
Let's personalize your content